Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Muhammad Usama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine and New Drug Development, China Medical University, Taichung, 406040, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Movement, Stage-Specific Embryonic Antigens, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University, National Science and Technology Council, Ministry of Health and Welfare.
Abstract (Originalsprache)
Although breast cancer treatment has evolved significantly in recent years, drug resistance remains a major challenge. To identify new targets for breast cancer, we found that stage-specific embryonic antigen 4 (SSEA-4) is expressed in all subtypes of breast cancer cell lines, and the increased expression of the associated enzymes β3GalT5 and ST3Gal2 correlates with poor recurrence-free survival (RFS) in breast cancer. We also found that SSEA-4 antibodies can be rapidly internalized into breast cancer cells, a property that makes SSEA-4 an attractive target for antibody-drug conjugates (ADCs). Furthermore, the SSEA-4 antibody conjugated to the anticancer agents showed efficacy against SSEA-4-positive breast cancer cells, including those resistant to PARP inhibitor, trastuzumab, and CDK7 inhibitor. In addition, SSEA-4 ADCs showed no efficacy in β3GalT5-knockout MDA-MB-231 cells, highlighting the essential role of SSEA-4 as the target antigen for ADCs activity. Our work shows that SSEA-4-ADCs could be a therapeutic option for breast cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine and New Drug Development, China Medical University, Taichung, 406040, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 406040, Taiwan.
- Research Center for Cancer Biology, China Medical University, Taichung, 406040, Taiwan.
- Department of Biological Sciences and Biotechnology, Hannam University, 34054, Daejeon, Republic of Korea.
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung, 406040, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 406040, Taiwan; Graduate Institute of Cell Biology, China Medical University, Taichung, 406040, Taiwan.
Förderung
- China Medical University
- National Science and Technology Council
- Ministry of Health and Welfare
Zitieren
APA
Usama, M., Hsu, Y. C., Safaei, M., Chen, C. Y., Han, K. H., Ho, Y. S., Yamaguchi, H., Li, Y. C., Hung, M. C., Wong, C. H., & Lin, C. W. (2025). Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217453
Vancouver
Usama M, Hsu YC, Safaei M, Chen CY, Han KH, Ho YS, et al. Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217453
BibTeX
@article{Usama2025,
author = {Usama, Muhammad and Hsu, Yu-Chieh and Safaei, Mahdieh and Chen, Chung-Yu and Han, Kyung Ho and Ho, Yuan-Soon and Yamaguchi, Hirohito and Li, Yi-Chuan and Hung, Mien-Chie and Wong, Chi-Huey and Lin, Chih-Wei},
title = {Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217453}
}
EUVIMED